Jun 2, 2009
By:Michelle Hoffman
Pharmaceutical Technology
Misleading the public about their investments—be it money or medicine—is unacceptable.
 |
Apr 2, 2009
By:Michelle Hoffman
Pharmaceutical Technology
Obama's cost-containment and science-innovation initiatives need to overlap.
|
Feb 2, 2009
By:Michelle Hoffman
Pharmaceutical Technology
FDA's role should not be overlooked as it has been in years past.
|
Jan 2, 2009
By:Michelle Hoffman
Pharmaceutical Technology
The incoming administration has renewed hope for stem cells, but less adequate copycats may follow.
|
Dec 2, 2008
By:Michelle Hoffman
Pharmaceutical Technology
China's quality approach to domestic versus exported products seems to be a lose-lose situation.
|
Nov 2, 2008
By:Michelle Hoffman
Pharmaceutical Technology
Pharma companies could benefit from the lessons learned in this fall's financial crisis.
|
Oct 2, 2008
By:Michelle Hoffman
Pharmaceutical Technology
Can previous trends of Democratic and Republican administrations predict industry's future?
|
Sep 2, 2008
By:Michelle Hoffman
Pharmaceutical Technology
Are hypersanitation trends a result of scaremongering or a lack of faith in medicine?
|
Aug 2, 2008
By:Michelle Hoffman
Pharmaceutical Technology
Legislative decisions to increase Medicare's formulary may lead to a fight over drug approvals.
|
| 
